Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab govitecan versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer
2024-512148-50-00Phase 3Authorised
- Sponsor
- Gilead Sciences
- Start
- Mar 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Sacituzumab govitecan with Docetaxel (2 arms). Primary endpoint: Overall survival. Planned start Mar 2022; status: authorised.
02
Drugs
sacituzumab govitecandocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-512148-50-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512148-50-00.